US Bancorp DE Reduces Stake in DaVita Inc. (NYSE:DVA)

US Bancorp DE decreased its stake in shares of DaVita Inc. (NYSE:DVA) by 27.0% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 2,973 shares of the company’s stock after selling 1,098 shares during the quarter. US Bancorp DE’s holdings in DaVita were worth $445,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. JPMorgan Chase & Co. increased its position in DaVita by 17.8% during the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after buying an additional 92,014 shares in the last quarter. KBC Group NV increased its position in DaVita by 0.8% during the fourth quarter. KBC Group NV now owns 316,155 shares of the company’s stock worth $47,281,000 after buying an additional 2,636 shares in the last quarter. BNP Paribas Financial Markets increased its position in DaVita by 23.9% during the third quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company’s stock worth $47,874,000 after buying an additional 56,389 shares in the last quarter. Nordea Investment Management AB increased its position in DaVita by 4.9% during the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company’s stock worth $39,712,000 after buying an additional 12,339 shares in the last quarter. Finally, FMR LLC increased its position in DaVita by 659.9% during the third quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after buying an additional 154,061 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 2.8 %

Shares of NYSE DVA opened at $142.57 on Thursday. DaVita Inc. has a 1 year low of $125.64 and a 1 year high of $179.60. The firm has a market cap of $11.41 billion, a price-to-earnings ratio of 13.28, a PEG ratio of 1.07 and a beta of 0.99. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The stock’s 50-day simple moving average is $159.28 and its 200-day simple moving average is $157.79.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, equities analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on DVA. Barclays raised their price target on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on DaVita in a report on Friday, February 21st. Finally, Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, DaVita has an average rating of “Hold” and an average price target of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.